Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 97% Improvement Relative Risk Case -30% Nemani et al. Fluvoxamine for COVID-19 Prophylaxis Is prophylaxis with fluvoxamine beneficial for COVID-19? Retrospective 1,958 patients in the USA (March - July 2020) More cases with fluvoxamine (not stat. sig., p=0.16) Nemani et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.10743 Favors fluvoxamine Favors control
Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System
Nemani et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.10743
Nemani et al., Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term.., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.10743
May 2022   Source   PDF  
  All Studies   Meta
Retrospective 1,958 consecutive psychiatric patients in the USA, showing higher cases and lower mortality with fluvoxamine, without statistical significance. There was only 25 fluvoxamine patients.
risk of death, 97.5% lower, RR 0.03, p = 1.00, treatment 0 of 16 (0.0%), control 38 of 953 (4.0%), NNT 25, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of case, 29.8% higher, RR 1.30, p = 0.16, treatment 16 of 25 (64.0%), control 953 of 1,933 (49.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Nemani et al., 6 May 2022, retrospective, USA, peer-reviewed, 12 authors, study period 8 March, 2020 - 1 July, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Abstract: Original Investigation | Psychiatry Association Between the Use of Psychotropic Medications and the Risk of COVID-19 Infection Among Long-term Inpatients With Serious Mental Illness in a New York State–wide Psychiatric Hospital System Katlyn Nemani, MD; Sharifa Z. Williams, DrPH; Mark Olfson, MD; Emily Leckman-Westin, PhD; Molly Finnerty, MD; Jammie Kammer, PhD; Thomas E. Smith, MD; Daniel J. Silverman, MD; Jean-Pierre Lindenmayer, MD; Gillian Capichioni, BS; James Clelland, PhD; Donald C. Goff, MD Abstract Key Points IMPORTANCE Individuals with serious mental illness are at increased risk of severe COVID-19 infection. Several psychotropic medications have been identified as potential therapeutic agents to prevent or treat COVID-19 but have not been systematically examined in this population. Question Is psychotropic medication use associated with differences in the risk of COVID-19 infection among adults with serious mental illness? OBJECTIVE To evaluate the associations between the use of psychotropic medications and the risk Findings In this cohort study of 1958 of COVID-19 infection among adults with serious mental illness receiving long-term inpatient inpatients with serious mental illness in psychiatric treatment. a statewide psychiatric hospital system, the use of second-generation DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study assessed adults with antipsychotic medications was serious mental illness hospitalized in a statewide psychiatric hospital system in New York between associated with a decreased risk of March 8 and July 1, 2020. The final date of follow-up was December 1, 2020. The study included 1958 COVID-19 infection; the largest consecutive adult inpatients with serious mental illness (affective or nonaffective psychoses) who association was observed with the use received testing for SARS-CoV-2 by reverse transcriptase–polymerase chain reaction or of paliperidone. Valproic acid use was antinucleocapsid antibodies and were continuously hospitalized from March 8 until medical associated with an increased risk of discharge or July 1, 2020. infection. Meaning These results suggest that EXPOSURES Psychotropic medications prescribed prior to COVID-19 testing. individual psychotropic medications are associated with differential risks of MAIN OUTCOMES AND MEASURES COVID-19 infection was the primary outcome, defined by a positive SARS-CoV-2 reverse transcriptase–polymerase chain reaction or antibody test result. The COVID-19 infection among patients with serious mental illness. secondary outcome was COVID-19–related death among patients with laboratory-confirmed infection. RESULTS Of the 2087 adult inpatients with serious mental illness continuously hospitalized during the study period, 1958 (93.8%) underwent testing and were included in the study; 1442 (73.6%) were men, and the mean (SD) age was 51.4 (14.3) years. A total of 969 patients (49.5%) had + Invited Commentary + Supplemental content Author affiliations and article information are listed at the end of this article. laboratory-confirmed COVID-19 infection that occurred while they were hospitalized; of those, 38 (3.9%) died. The use of second-generation antipsychotic medications, as a class, was associated with decreased odds of infection (odds ratio [OR], 0.62; 95% CI, 0.45-0.86), whereas the use of mood stabilizers was associated with increased odds of infection (OR, 1.23; 95% CI, 1.03-1.47). In a multivariable model..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop